Technology area: Biotechnology & Pharmaceuticals
8 pending office actions • 6 art units • 7 examiners • 0 of 8 (0%) have an AI response strategy ready
Spark Therapeutics Inc. has 8 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 7 examiners across 6 art units, indicating a broad prosecution footprint with some repeated examiner or assignment coverage. Portfolio management should combine centralized oversight with application-specific analysis.
NICOL, ALEXANDER W is the busiest examiner, with 2 pending matters. That concentration gives counsel one examiner relationship to monitor for consistent claim interpretation and response practice. The remaining matters are distributed across the other identified examination assignments, so uniform amendments may not be appropriate without reviewing each record.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (12%) |
| §103 only | 4 (50%) |
| §102 only | 1 (12%) |
| Double-patenting + other | 1 (12%) |
| Multi-statute (no §101) | 1 (12%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NICOL, ALEXANDER W | 2 | 42.7% | +43.6% |
| BRETZ, COREY LANE | 1 | 0.0% | +0.0% |
| WANG, RUIXUE | 1 | 55.9% | +19.0% |
| BLUMEL, BENJAMIN P | 1 | 70.7% | +30.6% |
| BATES, KEENAN ALEXANDER | 1 | 44.9% | +79.8% |
| TSAY, MARSHA M | 1 | 45.5% | +52.8% |
| GRABER, JAMES J | 1 | 46.5% | +57.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18685681 | Method of Enhancing Gene Therapy by Targeting cGAS-STING Pathway | BRETZ, COREY LANE | — |
| 18568530 | AAV VECTOR COLUMN PURIFICATION METHODS | WANG, RUIXUE | — |
| 17777954 | SECRETABLE PROTEIN INDUCED IMMUNE TOLERIZATION AND TREATMENT OF AUTOIMMUNE, ALLERGIC AND OTHER DISEASES AND DISORDERS | BLUMEL, BENJAMIN P | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16088693 | CELL LINE FOR RECOMBINANT PROTEIN AND/OR VIRAL VECTOR PRODUCTION | NICOL, ALEXANDER W | 36d overdue |
| 16627227 | AAV VECTOR COLUMN PURIFICATION METHODS | TSAY, MARSHA M | 18d overdue |
| 15780542 | SCALABLE METHODS FOR PRODUCING RECOMBINANT ADENO-ASSOCIATED VIRAL (AAV) VECTOR IN SERUM-FREE SUSPENSION CELL CULTURE SYSTEM SUITABLE FOR CLINICAL USE | GRABER, JAMES J | 22d |
| 18535857 | METHODS OF REGULATING ADENO-ASSOCIATED VIRUS PRODUCTION | NICOL, ALEXANDER W | — |
| 18568530 | AAV VECTOR COLUMN PURIFICATION METHODS | WANG, RUIXUE | — |
| 17777954 | SECRETABLE PROTEIN INDUCED IMMUNE TOLERIZATION AND TREATMENT OF AUTOIMMUNE, ALLERGIC AND OTHER DISEASES AND DISORDERS | BLUMEL, BENJAMIN P | — |
| 17309261 | IN VITRO ASSAY FOR DETECTING ENHANCERS AND INHIBITORS OF ADENO ASSOCIATED VIRUS (AAV) VECTOR TRANSDUCTION AND/OR DETECTING OR QUANTITATING ANTI-AAV BINDING ANTIBODIES | BATES, KEENAN ALEXANDER | — |
| Art Unit | Apps |
|---|---|
| 1634 | 2 |
| 1631 | 2 |
| 1635 | 1 |
| 1672 | 1 |
| 1671 | 1 |
| 1656 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18685681 | Method of Enhancing Gene Therapy by Targeting cGAS-STING Pathway | BRETZ, COREY LANE | 1635 | §102§103§112DP | Non-Final OA | — | Pending | Feb 22, 2024 |
| 18535857 | METHODS OF REGULATING ADENO-ASSOCIATED VIRUS PRODUCTION | NICOL, ALEXANDER W | 1634 | §102 | Non-Final OA | — | Pending | Dec 11, 2023 |
| 18568530 | AAV VECTOR COLUMN PURIFICATION METHODS | WANG, RUIXUE | 1672 | §103§112 | Non-Final OA | — | Pending | Dec 08, 2023 |
| 17777954 | SECRETABLE PROTEIN INDUCED IMMUNE TOLERIZATION AND TREATMENT OF AUTOIMMUNE, ALLERGIC AND OTHER DISEASES AND DISORDERS | BLUMEL, BENJAMIN P | 1671 | §101§102§103§112 | Non-Final OA | — | Pending | May 18, 2022 |
| 17309261 | IN VITRO ASSAY FOR DETECTING ENHANCERS AND INHIBITORS OF ADENO ASSOCIATED VIRUS (AAV) VECTOR TRANSDUCTION AND/OR DETECTING OR QUANTITATING ANTI-AAV BINDING ANTIBODIES | BATES, KEENAN ALEXANDER | 1631 | §103 | Non-Final OA | — | Pending | May 12, 2021 |
| 16627227 | AAV VECTOR COLUMN PURIFICATION METHODS | TSAY, MARSHA M | 1656 | §103Other | Final Rejection | 18d overdue | Pending | Dec 27, 2019 |
| 16088693 | CELL LINE FOR RECOMBINANT PROTEIN AND/OR VIRAL VECTOR PRODUCTION | NICOL, ALEXANDER W | 1634 | §103 | Non-Final OA | 36d overdue | Pending | Sep 26, 2018 |
| 15780542 | SCALABLE METHODS FOR PRODUCING RECOMBINANT ADENO-ASSOCIATED VIRAL (AAV) VECTOR IN SERUM-FREE SUSPENSION CELL CULTURE SYSTEM SUITABLE FOR CLINICAL USE | GRABER, JAMES J | 1631 | §103 | Final Rejection | 22d | Pending | May 31, 2018 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSpark Therapeutics Inc. has 8 pending office actions as of October 2026, spread across 6 art units and 7 examiners.
Alexander W Nicol has the most, with 2 of Spark Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
